Table 6.
Comparison of the Diagnostic Performance of the ADNEX Model for Different Subtypes of Ovarian Tumors
| ADNEX Models | Sensitivity (95% CI) (%) | Specificity (95% CI)(%) | PPV (95% CI) (%) | NPV (95% CI) (%) | Diagnose Accordance Rate (95% CI) (%) |
|---|---|---|---|---|---|
| Benign tumor | 74.0(65.1–81.6) | 94.3(88.0–97.9) | 93.6(87.0–97.0) | 76.2(70.2–81.3) | 83.5(78.0–88.1) |
| Borderline tumor | 60.0(36.1–80.9) | 84.8(79.1–89.4) | 27.9(19.3–38.6) | 95.6(92.6–97.4) | 82.6(77.0–87.3) |
| Stage I | 28.6(8.4–58.1) | 96.7(93.3–98.7) | 36.4(15.9–63.3) | 95.3(93.6–96.6) | 92.4(88.1–95.5) |
| Stage II–IV | 85.0(73.4–92.9) | 90.9(85.4–94.8) | 77.3(67.5–84.8) | 94.3(90.0–96.8) | 89.3(84.5–93.0) |
| Metastatic tumor | 45.5(16.7–76.6) | 97.7(94.6–99.2) | 50.0(25.3–74.7) | 97.2(95.3–98.3) | 95.1(91.4–97.5) |
Abbreviations: PPV, positive predictive value; NPV, negative predictive value.